Vertex Pharmaceuticals

VRTX

Market cap $114B

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

If you're looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech innovators.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 2:35 p.m. ET. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at Bernstein's 42nd Annual Strategic Decisions Con.

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.